JD Health International Inc. saw its stock price soar 5.20% during intraday trading on Thursday, reflecting significant positive investor sentiment.
The sharp rise appears to be driven by bullish analyst outlooks. Both UBS and HSBC maintained their Buy ratings on the stock, with UBS setting a price target of HK$70.70 and HSBC setting a target of HK$79.50. These reaffirmations of confidence from major financial institutions likely contributed to the strong buying pressure observed in the market.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments